ROCKVILLE, Md. & NEW YORK, August 02, 2024–(BUSINESS WIRE)–OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company.
That’s a mouthful. Before we continue, it seems that Mouthful has interested many investors.
OSTX aims to identify lead candidates for treating osteosarcoma and other solid tumors for clinical development, regulatory approval, and commercialization. Starting with the most common genetic mutation found in Osteosarcoma, OS Therapies has identified a lead candidate in HER-2 Osteosarcoma with a goal of rapid clinical and regulatory analysis and review. This action will be immediately followed in parallel with the OST-tADC development.
The biotech is quite simple. Take OSTX’s OST-HER2 therapy as an example. This could be the reason investors rocked the graph. One of the nasty aspects of cancer is metastasis, which raises the possibility of imminent death.
This off-the-shelf immunotherapy treatment is designed to prevent metastasis, delay recurrence, kill primary tumours expressing HER2 and increase overall survival.
- AOST-2121 (trial site) has enrolled 41 patients treated with OST-HER2 at 21 clinical trial sites across the United States.
- Some patients remain in the active treatment stage, with the remainder in follow-up for overall survival.
- The primary endpoints for the AOST-2121 study are Event Survival (‘EFS,’ defined as the absence of recurrence of primary tumour or metastasis) at 12 months and Overall Survival at 36 months with interim Overall Survival endpoints at 12 months and 24 months.
- Topline EFS data, interim 1-year OS data, and additional secondary data analyses are expected to be reported in the fourth quarter of 2024.
- In over 40 years, no novel therapeutic interventions have improved the clinical outcomes for patients with resected, recurrent osteosarcoma.
More?
- Advances in the treatment of osteosarcoma have improved the outlook for this cancer.
- After treatment for osteosarcoma, people sometimes face late effects from the vital therapies used to control the cancer.
- Healthcare professionals often suggest lifelong monitoring for side effects after treatment.
OSTEOSARCOMA
- RARE BONE CANCER
- ATTACKS KIDS AND ADULTS
- AGGRESSIVE AND RECURS
- OS THERAPIES WERE CREATED TO IDENTIFY POTENTIAL TREATMENTS FOR OS THAT NEEDED ASSISTANCE PROVING THEY WORKED AND COULD BE BROUGHT TO PATIENTS.
- Advances in the treatment of osteosarcoma have improved the outlook for this cancer.
- After treatment for osteosarcoma, people sometimes face late effects from the vital therapies used to control the cancer.
- Healthcare professionals often suggest lifelong monitoring for side effects after treatment.
High grade: Most osteosarcomas are high grade, meaning they will probably grow and spread quickly if not treated. The usual treatment for these cancers is as follows:
- Biopsy to establish the diagnosis
- Chemotherapy (chemo), usually for about ten weeks
- Surgery to remove the tumour, preferably by the same surgeon who did the biopsy. If cancer is found at the edge of the surgery specimen (meaning some tumour might have been left behind), a second surgery might be done to try to remove any remaining cancer. Radiation therapy might be given to the area as well.
- More chemotherapy (for up to a year). If the initial chemotherapy killed most of the cancer cells, the same drugs are often given again after surgery. If the initial chemotherapy didn’t work well, different drugs might be tried (although not all doctors agree that switching drugs is needed).
Investors have keyed into OSTX’s unique and deeply important research. The treatment for bone cancer is impressive, as it is aimed at a rare disease. Other unique therapies deal with solid tumours in various diseases.
Remember this, if nothing else: therapy OST-HER2, this off-the-shelf immunotherapy treatment, is designed to prevent metastasis, delay recurrence, kill primary tumours expressing HER2 and increase overall survival.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
